Skip to main content
Signal8

Amplia Therapeutics Limited (INNMF)

Sector: Biotechnology

Industry: Biotechnology

Amplia Therapeutics Limited logo

Amplia Therapeutics Limited

OTC:INNMFHealthcare
-15.56%$0.0535
CLOSED
Mkt Cap$27.46M
EV-
Float479.04M
O/S513.31M
VOL475 sh
$ Vol$25
RVOL0.04×
Inst Own-
Net Cash/Sh-
Dilution
Amplia Therapeutics Limited logoOTC:INNMFClosed$0.0535-15.56%
Historical Data
DateOpenHighLowCloseVolume
Nov 12, 20260.05350.05350.05350.0535475
Nov 11, 20260.05520.06340.05520.06346,080
Nov 9, 20260.06960.06960.05780.05784,088
Nov 5, 20260.06440.06440.06440.06441,750
Nov 3, 20260.05870.05870.05870.05874,600
Oct 28, 20260.05400.05400.05400.05406,000
Oct 23, 20260.05500.05500.05500.05505,000
Oct 19, 20260.06000.06000.05000.052957,250
Oct 16, 20260.05400.05750.05150.057560,000
Oct 14, 20260.06840.07760.05000.075066,000
Oct 13, 20260.06350.07200.05010.050164,612
Oct 12, 20260.09050.09050.09050.0905120,000
Oct 9, 20260.08000.08000.07130.071312,500
Oct 7, 20260.05000.07710.05000.070022,412
Oct 5, 20260.07000.08000.07000.080030,000
Oct 2, 20260.08000.08000.08000.080035,000
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

Established in 2000 and headquartered in Melbourne, Australia, Amplia Therapeutics Limited is a pharmaceutical firm dedicated to the discovery and development of focal adhesion kinase (FAK) inhibitors.

The company's therapeutic endeavors are concentrated on oncology (cancer) and chronic fibrotic diseases.

Its drug development pipeline includes AMP945, a FAK inhibitor that has successfully completed Phase I clinical trials and is being explored for its efficacy in treating pancreatic cancer, idiopathic pulmonary fibrosis, and a broader spectrum of cancerous and fibrotic conditions. Another compound, AMP886, is also under development for potential applications in cancer and fibrotic disorders. Amplia Therapeutics maintains a strategic collaboration with the Garvan Institute of Medical Research in Sydney, and the company adopted its current name in September 2018, having previously operated as Innate Immunotherapeutics Limited.

Key Metrics
Market Cap$27.46M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 513.31M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryAUAU
IPO Date-
Shares Outstanding513.31M
Authorized Shares
Float479.04M
52-Week Range
$0.0500$0.2700
$0.0535(2nd percentile)
Volume
Average Daily Volume10.65K
475 today vs 10.65K avg(-96%)

30d Avg

10.65K

60d Avg

29.88K

90d Avg

27.44K

Earnings
Dividend History
No dividend history available

Amplia Therapeutics Limited (OTC: INNMF) traded at $0.0535 on Nov 12, 2026, down 15.56% from the previous close of $0.0634. 52-week range: $0.0500 to $0.2700. The company is in the Healthcare sector (Biotechnology).